Salbutamol hemisulfate salt
SIGMA/S5013 - ≥98%
Synonym: α-([t-Butylamino]methyl)-4-hydroxy-m-xylene-α,α′-diol; Albuterol
CAS Number: 51022-70-9
Empirical Formula (Hill Notation): C13H21NO3 · 0.5H2O4S
Molecular Weight: 288.35
EC Number: 256-916-8
MDL Number: MFCD00055200
Linear Formula: C13H21NO3 · 1/2H2SO4
Product Type: Chemical
| assay | ≥98% |
| InChI | 1S/2C13H21NO3.H2O4S/c2*1- |
| InChI key | BNPSSFBOAGDEEL-UHFFFAOYSA |
| originator | GlaxoSmithKline |
| Quality Level | 200 ![]() |
| SMILES string | OS(O)(=O)=O.CC(C)(C)NCC(O |
| solubility | 1 M NaOH: 50 mg/ml, clear to slightly hazy, yellow-green |
| Application: | Salbutamol hemisulfate salt has been used as reference standards of drugs for the validation of β-agonist residue. |
| Application: | Salbutamol hemisulfate salt was used as standard in analysis of fortified meat for LABA content using ELISA kits.3 It was used to study the response of prostaglandin 2α to various β-adrenergic agonists in cultured bovine endometrial cells.4 |
| Biochem/physiol Actions: | β2-Adrenergic receptor agonist. |
| Biochem/physiol Actions: | Salbutamol is a β2 adrenoceptor agonist with short acting bronchodilation and anti-inflammatory effects. It relaxes the airway smooth muscles and inhibits bronchoconstriction induced by adenosine-5′ -monophosphate (AMP).1 Salbutamol is particularly effective in treatment of asthma as it provides immediate relief.2 |
| Biochem/physiol Actions: | Salbutamol is a β2 adrenoceptor agonist with short acting bronchodilation and anti-inflammatory effects. It relaxes the airway smooth muscles and inhibits bronchoconstriction induced by adenosine-5′ -monophosphate (AMP). Salbutamol is particularly effective in treatment of asthma as it provides immediate relief. Salbutamol is one of the most popular short-acting BA (SABA). It is useful in treating the symptoms of EIB (exercise induced bronchospasm). |
| Features and Benefits: | This compound is featured on the β-Adrenoceptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: | This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 25 mg in glass insert |
| Packaging: | 50, 100, 250 mg in glass bottle |
| Symbol | ![]() GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | H317 - H351 - H361fd |
| Precautionary statements | P202 - P261 - P272 - P280 - P302 + P352 - P308 + P313 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 2 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% |
| UNSPSC | 12352200 |



